ArticleEBioMedicine2015
Successful Treatment of Intracranial Glioblastoma Xenografts With a Monoamine Oxidase B-Activated Pro-Drug.
Article in EBioMedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Deepening the Understanding of Platelet-Derived RNA as Biomarker for Glioblastoma Through GSEA, TDEA, and Elastic Net Regularization Analysis.Cancer reports (Hoboken, N.J.) · 2026Article
- Monoamine Oxidase B in Cancers: Implications for Therapeutics and Prognosis.Journal of inflammation research · 2025Review
- Targeting MAO-B with Small-Molecule Inhibitors: A Decade of Advances in Anticancer Research (2012-2024).Molecules (Basel, Switzerland) · 2024Review
- Expression of Amine Oxidase Proteins in Adrenal Cortical Neoplasm and Pheochromocytoma.Biomedicines · 2023Article
- Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: At a glance.Frontiers in cell and developmental biology · 2022Review
- Article
- Nanomedicine-based immunotherapy for central nervous system disorders.Acta pharmacologica Sinica · 2020Review
- Evolution of Experimental Models in the Study of Glioblastoma: Toward Finding Efficient Treatments.Frontiers in oncology · 2020Review
- Mitochondrial Dysfunction, Macrophage, and Microglia in Brain Cancer.Frontiers in cell and developmental biology · 2020Article
- Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Monoamine Oxidase B in Renal Cell Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Article
- Current trends in mouse models of glioblastoma.Journal of neuro-oncology · 2017Review
- ATP Maintenance via Two Types of ATP Regulators Mitigates Pathological Phenotypes in Mouse Models of Parkinson's Disease.EBioMedicine · 2017Article
- CNS Anticancer Drug Discovery and Development: 2016 conference insights.CNS oncology · 2017Article
- Article
- Intracranial Glioblastomas: New Hope for an Effective Treatment.EBioMedicine · 2015Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The last major advance in the treatment of glioblastoma multiforme (GBM) was the introduction of temozolomide in 1999. Treatment with temozolomide following surgical debulking extends survival rate compared to radiotherapy and debulking alone. However, virtually all glioblastoma patients experience disease progression within 7 to 10 months. Although many salvage treatments, including bevacizumab, rechallenge with temozolomide, and other alkylating agents, have been evaluated, none of these clearly improves survival. Monoamine oxidase B (MAOB) is highly expressed in glioblastoma cell mitochondria, and mitochondrial function is intimately tied to treatment-resistant glioblastoma progression. These glioblastoma properties provide a strong rationale for pursuing a MAOB-selective pro-drug treatment approach that, upon drug activation, targets glioblastoma mitochondria, especially mitochondrial DNA. MP-MUS is the lead compound in a family of pro-drugs designed to treat GBM that is converted into the mature, mitochondria-targeting drug, P(+)-MUS, by MAOB. We show that MP-MUS can successfully kill primary gliomas in vitro and in vivo mouse xenograft models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.